STOCK TITAN

BridgeBio Pharma Inc - BBIO STOCK NEWS

Welcome to our dedicated news page for BridgeBio Pharma (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on BridgeBio Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BridgeBio Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BridgeBio Pharma's position in the market.

Rhea-AI Summary
BridgeBio receives positive feedback from FDA and EU EMA on trial design for infigratinib in achondroplasia, clearing path for Phase 3 trial initiation by end of 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
clinical trial
-
Rhea-AI Summary
BridgeBio announces positive results from Phase 3 study of acoramidis for patients with ATTR-CM. Primary endpoint met with a Win Ratio of 1.8 (p<0.0001). Consistent treatment benefit observed across key subgroups. 81% survival rate on acoramidis approaches US database rate (~85%). Mean annual CVH rate on acoramidis approaches US Medicare rate (~0.26). Improvement observed in NT-proBNP and 6MWD measures. Acoramidis achieves near-complete stabilization of TTR. Well-tolerated with no safety concerns. NDA to be filed with FDA by end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
BridgeBio Pharma to present Phase 3 results of acoramidis in ATTR-CM at ESC Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.7%
Tags
conferences clinical trial
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced the grant of 26,657 restricted stock units to seven new employees. The shares will vest over time, subject to continued employment, under the Amended and Restated 2019 Inducement Equity Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
none
-
Rhea-AI Summary
BridgeBio Pharma, Inc. reported positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy. The study showed a highly statistically significant result on the primary endpoint with a Win Ratio of 1.8. The company plans to file a New Drug Application (NDA) for acoramidis with the FDA by the end of 2023. BridgeBio also presented positive results from other clinical trials and provided updates on its pipeline programs. The company ended the quarter with $353 million in cash and investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
earnings
-
Rhea-AI Summary
BridgeBio Pharma announces potential accelerated approval for BBP-418 in patients with LGMD2I/R9 and initiates Phase 3 FORTIFY clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
clinical trial
Rhea-AI Summary
BridgeBio Pharma announces the grant of restricted stock units to new employees. The units will vest on specific dates based on continued employment. The awards were made under the company's Inducement Equity Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
none
-
Rhea-AI Summary
BridgeBio Pharma reports positive results from its Phase 3 study of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). The study showed a highly statistically significant improvement in the primary endpoint, with a Win Ratio of 1.8 (p<0.0001). Acoramidis demonstrated a clinically meaningful and consistent separation on all measures of mortality, morbidity, function, and quality of life. The on-treatment survival rate was 81% compared to 74% for placebo, with a relative risk reduction of 25%. A 50% relative risk reduction (p<0.0001) was observed on the frequency of cardiovascular-related hospitalization. The company plans to file a New Drug Application (NDA) with the FDA by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
75.85%
Tags
clinical trial
-
Rhea-AI Summary
BridgeBio Pharma, Inc. will host an investor call on July 17 to share topline results from the Phase 3 ATTRibute-CM clinical study in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
partnership
BridgeBio Pharma Inc

Nasdaq:BBIO

BBIO Rankings

BBIO Stock Data

5.70B
113.02M
5.37%
92.14%
7.27%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Palo Alto

About BBIO

we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.